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SUPPLEMENTARY APPENDIX

Online Supplementary Design and Methods
Flow cytometric analysis for surface membrane expression of B-cell activating factor and its receptors
To analyze for cell surface expression of B-cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI), or B-cell activating factor receptor (BAFFR), mantle cell lymphoma (MCL) cells (1x10 5 /100 μL) were stained with saturating amounts of the appropriate phycoerythrin (PE)-or fluorescein isothiocyanate (FITC)-conjugated antibody (eBioscience, San Diego, CA, USA) for 30 min at 4°C in FACS buffer (phosphate-buffered saline supplemented with 0.5% bovine serum albumin). After having been washed twice in FACS buffer, the cells were analyzed using a FC500 flow cytometer (Beckman Coulter Immunology, Hialeah, FL, USA). In each experiment the appropriate PE-or FITC-conjugated isotype control antibody was used to determine background staining.
Western blotting
MCL cells were cultured alone or co-cultured with human mesenchymal stem/stromal cells (hMSC) or MS5 stromal cells. After 5 days in culture, cells were harvested, washed and lysed using lysis buffer [50 mM HEPES (pH 7.4), 150 mM NaCl, 1% Triton X-100, 30 mM sodium pyrophosphate, EDTA, 2 mM Na3VO4, 5 mM NaF, 1 mM phenylmethyl sulfonyl fluoride, 5 g/mL leupeptin, and 5 g/mL aprotinin). Cell lysates were subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membranes, and immunoblotted. Specific antibodies for bcl-2, and PARP, were purchased from Cell Signaling Technology (Beverly, MA, USA). Antigen-antibody complexes were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). Blots were stripped and re-probed with anti-actin antibody (Sigma-Aldrich, St Louis, MO, USA) to ensure equivalent protein loading.
Annexin V-propidium iodide staining
Apoptotic cells were detected using annexin V-FITC apoptosis detection kit I (Beckman Coulter), according to the manufacturer's instructions. Briefly, MCL cells (1x10 6 ) were cultured in culture medium alone, or with either MS-5 cells or hMSC and harvested on day 5. MCL cells were washed twice with icecold phosphate-buffered saline and resuspended (1x10 6 cells/mL) in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). MCL cells (1x10 5 ) were incubated with annexin V-FITC and propidium iodide for 15 min at room temperature. The cells were analyzed using CXP Cytomics software on an FC500 flow cytometer (Beckman Coulter Immunology, Hialeah, FL, USA).
Cell viability assays
For the determination of cell number and viability, unfractionated MCL cells (1 x 10 4 /cm 2 ) were seeded into T-25 flasks containing either α-MEM (control) alone or with MS-5 or hMSC (90-100% confluency). At the indicated times MCL cells were carefully removed from the monolayer. The monolayer was observed by microscopy to ensure that it was not disrupted). Cell number and viability were measured using trypan blue exclusion on a ViCell Cell Viability Analyzer (Beckman Coulter; Fullerton, CA). The Vicell parameters (size and circularity) were adjusted to discriminate MCL cells from stromal cells. The optimal settings were determined from doping experiments in which different ratios of MCL cells and stromal cells were counted in the Vicell (data not shown). In the experiments comparing adherent and non-adherent MCL populations, viability was determined by staining each population with hCD45-Cy7 and 7-AAD followed by flow cytometry.
Cell adhesion assay
For the quantitative determination of adhesive MCL-hMSC interactions, primary hMSC were seeded into 96-well plates and grown for 48 h to confluency. Then 2x10 6 primary MCL cells were labeled using the Vybrant CFDA SE Cell tracer kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The labeled cells were washed three times in α-MEM and 1x10 5 cells were added to each well of the 96-well plate. After overnight incubation at 37°C, the non-adherent cells were removed and the plates were washed twice in phosphate-buffered saline. Fluorescence was measured in a fluorescent plate reader (Victor-3; Perkin Elmer) and the number of adherent cells was determined from a standard curve constructed by using the fluorescence of 100 μL aliquots with a known number of labeled cells added to a sister plate treated as above.
Quantification and neutralization of B-cell activating factor
Recombinant human BAFF and recombinant human BAFFRFc (decoy receptor) which binds specifically to BAFF and neutralizes its effect, were purchased from Axxora (San Diego, CA, USA). Levels of soluble BAFF in MCL, hMSC, and MCL-hMSC co-culture conditioned α-MEM were quantified in triplicate using commercial enzyme-linked immunosorbent (ELISA) kits (Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions. In some experiments used to determine the source of soluble BAFF, MCL or stromal cells were treated with 1% paraformaldehyde before co-culture.
Chemotaxis assay
Chemotaxis experiments were performed using transwells (5 μ pore; Costar, Corning, NY, USA). MCL cells were washed and resuspended in α-MEM with 1% fetal bovine serum. These cells ( 5x10 5 ) were seeded into the upper chamber and 1 mL of medium containing the indicated concentration of BAFF, CXCL12, CXCL13 and the BAFF decoy receptor (BAFFR-Fc) was added to the bottom chamber. Pertussis toxin (PTX) was used for inhibition of cell chemotaxis. In experiments to determine whether NF-κB plays a role in MCL chemotaxis, MCL cells were infected with either AdGFP (a negative control) or adenovirus containing either dominant-negative IKK1 (IKK1dn) or dominant-negative IKK2 (IKK2dn) (known inhibitors of NF-κB2 and NF-κB1 activation, respectively). After 18 h at 37°C, migrated cells were enumerated by a hemocytometer.
Nuclear factor-κB activation
After the indicated treatment, nuclear extracts were prepared and NF-κB activation was determined by an ELISA kit according to the manufacturer's instruction (Trans-AM NF-κB Family; Active Motif, Carlsbad, CA, USA).
RNA isolation and quantitative reverse transcriptase polymerase chain reaction analysis
Total RNA isolation was performed using the RNAEasy Kit (Qiagen Inc. Valencia, CA, USA) in accordance with the manufacturer's instructions. At least 1x10 6 cells were harvested from controls and treated cells. Only RNA samples with A260/A280 absorbance ratios between values of 1.8-2.0 were used for quantitative real-time polymerase chain reaction (RT-PCR) experiments. Quantitative PCR experiments were carried out in a total volume of 21 μL on 50-100ng of RNA using Taqman Universal Master Mix (Applied Biosystems). Human b-actin primers (Applied Biosystems) were used as the endogenous control to normalize expression values of mRNA with the ΔΔCT method. BAFF (Hs00198106), IKK1 (Hs00175141) and IKK2 (Hs0023387) probes and primers were purchased from Applied Biosystems.
Long-term cultures on human mesenchymal stem/stromal cells
MCL cells and CBBC were plated at a density of 4x10 4 cells/cm 2 on a pre-established confluent layer of irradiated (25 Gy) hMSC stromal cells (MCL-to-hMSC ratio of 10:1) and maintained at 37°C in 5% CO2. Once a week, culture populations were halved by carefully removing half of the medium from each culture vessel and adding an equal volume of fresh α-MEM. Every 4 weeks non-adherent cells were removed from the flask and saved. The adherent cells were removed from the flask by the addition of enzyme-free cell disassociation solution (Invitrogen, Carlsbad, CA, USA) followed by two washes in α-MEM. The adherent and non-adherent cells were pooled, counted and MCL cells were then isolated by positive selection isolation using anti-human CD45-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA, USA). Cell purity was then determined by immunophenotyping (CD19, CD3 and CD105). Cells were CD19 + (97±3%), CD105 (3±3%) and no CD3 cells were detected. After MCL isolation the cell concentration was adjusted to 1x10 6 /mL and seeded onto a flask containing a fresh pre-established confluent layer of irradiated (25Gy) hMSC stromal cells (MCL-to-hMSC ratio of 10:1). This was repeated every 4 weeks.
To determine the effects of long-term culture of MCL cells, samples obtained from week 84 and 197 (arrows) cultures were evaluated for immunophenotype (CD3, CD19, CD5, CD23), t(11;14) translocation by fluorescence in situ hybridization and their ability to grow in the absence or presence of hMSC as described above.
Drug toxicity assay
In this series of experiments, MCL cells from six patients were cultured in α-MEM alone or containing doxorubicin (0.33-900 nM), bortezomib (5-160 nM) or fludarabine (5-160 mg/mL). All drugs were obtained from the CINJ research pharmacy. To evaluate the role of BAFF in MCL drug resistance, MCL cells were cultured in either α-MEM (control) or together with hMSC ± 10 μg/mL of the decoy receptor BAFFR-Fc. MCL cell (non-adherent and adherent) viability after 72 h of treatment was determined by staining cells with hCD45-CY7 and 7-AAD followed by flow cytometric analysis. In addition, to help distinguish between MCL cells and stromal cells, we used a lymphocyte gate that excluded large granular stromal cells based on their forward-and side-scatter characteristics.
